Trevi Therapeutics/$TRVI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Trevi Therapeutics
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
Ticker
$TRVI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
31
ISIN
US89532M1018
Website
TRVI Metrics
BasicAdvanced
$647M
-
-$0.44
0.62
-
Price and volume
Market cap
$647M
Beta
0.62
52-week high
$7.39
52-week low
$2.30
Average daily volume
1.1M
Financial strength
Current ratio
15.383
Quick ratio
15.106
Long term debt to equity
0.685
Total debt to equity
0.962
Interest coverage (TTM)
-17,029.33%
Management effectiveness
Return on assets (TTM)
-34.41%
Return on equity (TTM)
-55.12%
Valuation
Price to book
6.39
Price to tangible book (TTM)
6.39
Price to free cash flow (TTM)
-16.399
Growth
Earnings per share change (TTM)
31.48%
3-year earnings per share growth (CAGR)
-29.72%
What the Analysts think about TRVI
Analyst ratings (Buy, Hold, Sell) for Trevi Therapeutics stock.
TRVI Financial Performance
Revenues and expenses
TRVI Earnings Performance
Company profitability
TRVI News
AllArticlesVideos
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
Seeking Alpha·3 weeks ago
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
Benzinga·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Trevi Therapeutics stock?
Trevi Therapeutics (TRVI) has a market cap of $647M as of May 30, 2025.
What is the P/E ratio for Trevi Therapeutics stock?
The price to earnings (P/E) ratio for Trevi Therapeutics (TRVI) stock is 0 as of May 30, 2025.
Does Trevi Therapeutics stock pay dividends?
No, Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Trevi Therapeutics dividend payment date?
Trevi Therapeutics (TRVI) stock does not pay dividends to its shareholders.
What is the beta indicator for Trevi Therapeutics?
Trevi Therapeutics (TRVI) has a beta rating of 0.62. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.